---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-22-000034"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T04:53:45.235174+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma Q2 revenue $932.9M (+24% YoY), affirms FY2022 guidance, net leverage target met early

## Summary
- Q2 2022 total revenues $932.9M, up 24% YoY; strong commercial execution across franchises.
- 2022 total revenue guidance affirmed at $3.5-3.7B; GAAP guidance updated for FX movements.
- Net leverage ratio 3.2x, achieving target six months ahead of schedule, providing balance sheet flexibility.
- Milestones: more patients on Xywav than Xyrem; JZP458 MAA submitted to EMA; JZP815 IND cleared by FDA.
- Divested Sunosi to sharpen focus on strategic priorities; pipeline expanded with JZP441 and JZP898.

## SEC filing metadata
- accession: 0001232524-22-000034
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252422000034/0001232524-22-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252422000034/jazz-20220803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-22-000034
- JSON: https://secwatch.observer/filing/0001232524-22-000034.json
- Plain text: https://secwatch.observer/filing/0001232524-22-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.